Evaluating the landscape and characteristics of endometriosis research published between 1990 and 2024
This study analyzed 536 endometriosis RCTs from 1990-2024, finding a rise in complementary therapy research and a high proportion underpowered to detect clinically significant effects, with the US and China leading publications.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
This bibliometric analysis evaluated 536 randomized controlled trials on endometriosis published between 1990 and 2024 to assess trends in management types, geographic origins, and statistical power. The study found that medical management dominated the literature, with a significant portion focusing on GnRH analogues despite their status as second-line treatments, while complementary therapies saw a sharp rise in recent years. A major limitation identified was that over half of the trials with continuous outcomes were underpowered at 90% power to detect anything but large effect sizes, suggesting potential resource inefficiency. This paper is centrally about endometriosis — specifically analyzing the landscape, methodology, and power limitations of clinical trials investigating its treatment.
Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works
Abstract
Full text
3,766 characters
· extracted from
oa-html
· 4 sections
· click to expand
Abstract
Methods
Results
Conclusion
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (31)
- Complementary therapies for endometriosis associated pain: An extensive survey via openalex
- Endometriosis via openalex
- Fluid and pharmacological agents for adhesion prevention after gynaecological surgery via openalex
- Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density via openalex
- Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries via openalex
- Top ten endometriosis research priorities in the UK and Ireland via openalex
- W2603257905 via openalex
- W2769383275 via openalex
- W2809266094 via openalex
- W2946187833 via openalex
- W2983879675 via openalex
- W2995826184 via openalex
- W3097763105 via openalex
- W3123416850 via openalex
- W3123554164 via openalex
- W3158229501 via openalex
- W3210395850 via openalex
- W2135010675 via openalex
- W4214738619 via openalex
- W4214754424 via openalex
- W4225795233 via openalex
- W4234160457 via openalex
- W2032541700 via openalex
- W4280645308 via openalex
- W4308055778 via openalex
- W4383483325 via openalex
- W4387925226 via openalex
- W4408936335 via openalex
- W4409483458 via openalex
- W2000544357 via openalex
- W2576273795 via openalex
SciLite annotations
chemicals 3
Source provenance
- europepmc
- last seen: 2026-11-21T06:17:04.340742+00:00
- openalex
- last seen: 2026-10-26T06:07:52.047309+00:00
- pubmed
- last seen: 2026-11-21T06:09:49.980590+00:00
- scilite
- last seen: 2026-11-08T10:40:02.467495+00:00